Imunon, INC. (IMNN) — SEC Filings

Overview

Imunon, INC. (IMNN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Mar 31, 2026: Imunon, Inc. (IMNN) is a clinical-stage biotechnology company focused on developing non-viral DNA technology for innovative treatments. The company's lead program, IMNN-001, an immunotherapy for advanced ovarian cancer, is currently in a Phase 3 clinical trial (OVATION 3) after completing a Phase 2

Sentiment Summary

Across 48 filings, the sentiment breakdown is: 7 bearish, 40 neutral, 1 mixed. The dominant filing sentiment for Imunon, INC. is neutral.

Filing Type Overview

Imunon, INC. (IMNN) has filed 3 10-K, 30 8-K, 5 10-Q, 4 S-1/A, 2 S-1, 2 SC 13G, 1 SC 13G/A, 1 DEF 14A with the SEC between Jan 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (48)

• Imunon's Ovarian Cancer Drug Advances to Phase 3, Showing Strong Early Efficacy — 10-K · Mar 31, 2026 Risk: high
  Imunon, Inc. (IMNN) is a clinical-stage biotechnology company focused on developing non-viral DNA technology for innovative treatments. The company's lead progr
• Imunon, Inc. Files 8-K for Financial Results — 8-K · Mar 31, 2026 Risk: low
  Imunon, Inc. filed an 8-K on March 31, 2026, reporting on its Results of Operations and Financial Condition. The filing includes financial statements and exhibi
• 8-K Filing — 8-K · Dec 31, 2025
• Imunon Narrows Losses by 29.5%, Cash Dwindles Amid Phase 3 Trial — 10-Q · Nov 13, 2025 Risk: high
  Imunon, Inc. (IMNN) reported a net loss of $10.27 million for the nine months ended September 30, 2025, a significant improvement from the $14.56 million net lo
• Imunon, Inc. Faces Delisting Concerns — 8-K · Aug 28, 2025 Risk: high
  Imunon, Inc. filed an 8-K on August 27, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company, formerly known as Cel
• Imunon Posts Continued Losses Amidst Zero Revenue — 10-Q · Aug 5, 2025 Risk: high
  Imunon, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its prior year periods. The company posted a net loss of $3.5
• Imunon, Inc. Files 8-K: Other Events & Financials — 8-K · Jul 28, 2025 Risk: low
  Imunon, Inc. filed an 8-K on July 28, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific details about
• Imunon, Inc. Files 8-K with Key Corporate Updates — 8-K · Jul 23, 2025 Risk: medium
  Imunon, Inc. filed an 8-K on July 23, 2025, reporting events as of July 21, 2025. The filing indicates material modifications to the rights of security holders,
• Imunon, Inc. Files 8-K: Other Events & Financials — 8-K · Jul 22, 2025 Risk: low
  Imunon, Inc. filed an 8-K on July 22, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific details about
• Imunon, Inc. Faces Delisting Concerns, Director Changes — 8-K · Jul 14, 2025 Risk: high
  Imunon, Inc. filed an 8-K on July 14, 2025, reporting a notice of delisting or failure to satisfy continued listing rules, as well as changes in directors and o
• Imunon, Inc. Files 8-K on Security Holder Rights and Bylaws — 8-K · Jul 11, 2025 Risk: medium
  Imunon, Inc. filed an 8-K on July 11, 2025, reporting material modifications to the rights of security holders, amendments to its articles of incorporation or b
• Imunon, Inc. Files 8-K: Board and Compensation Updates — 8-K · Jun 13, 2025 Risk: low
  On June 13, 2025, Imunon, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing also includes
• Imunon, Inc. Files 8-K for Other Events — 8-K · Jun 9, 2025 Risk: medium
  Imunon, Inc. (formerly Celsion Corp) filed an 8-K on June 9, 2025, reporting "Other Events." The filing does not contain specific details about the nature of th
• Imunon, Inc. Faces Delisting Notice — 8-K · May 30, 2025 Risk: high
  Imunon, Inc. filed an 8-K on May 30, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The company, formerly known as Celsio
• Imunon, Inc. Files 8-K: Material Agreement, Equity Sales — 8-K · May 27, 2025 Risk: medium
  On May 23, 2025, Imunon, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and other event
• Imunon, Inc. Relocates Principal Executive Offices — 8-K · May 22, 2025 Risk: low
  On May 22, 2025, Imunon, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 997 Lenox Drive, Suite 100, Law
• Imunon, Inc. Faces Delisting Concerns — 8-K · May 20, 2025 Risk: high
  Imunon, Inc. filed an 8-K on May 20, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company's principal executive off
• Imunon, Inc. Files S-1/A Amendment — S-1/A · May 19, 2025 Risk: medium
  Imunon, Inc. filed an S-1/A amendment on May 19, 2025, for its registration statement under the Securities Act of 1933. The company, formerly known as Celsion C
• Imunon, Inc. Files 8-K: Material Agreement & Equity Sales — 8-K · May 13, 2025 Risk: medium
  On May 12, 2025, Imunon, Inc. filed an 8-K report detailing a material definitive agreement and unregistered sales of equity securities. The filing also include
• Imunon, Inc. Files Q1 2025 10-Q Report — 10-Q · May 12, 2025 Risk: medium
  Imunon, Inc. filed its quarterly report for the period ending March 31, 2025. The company, formerly known as Celsion Corp, is based in Lawrenceville, NJ. Financ
• Imunon, Inc. Files S-1 Registration Statement — S-1 · Apr 4, 2025 Risk: medium
  Imunon, Inc. filed an S-1 registration statement on April 4, 2025, to register securities under the Securities Act of 1933. The company, formerly known as Celsi
• Imunon, Inc. Files 8-K — 8-K · Mar 24, 2025 Risk: low
  Imunon, Inc. filed an 8-K on March 24, 2025, reporting other events and financial statements. The company, formerly known as Celsion Corp and Cheung Laboratorie
• 10-K Filing — 10-K · Feb 27, 2025
• Imunon, Inc. Files 8-K on Executive Changes and Financials — 8-K · Feb 10, 2025 Risk: medium
  Imunon, Inc. filed an 8-K on February 10, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of certain offic
• Imunon, Inc. Faces Delisting Concerns — 8-K · Nov 27, 2024 Risk: high
  Imunon, Inc. filed an 8-K on November 27, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The company, formerl
• SC 13G Filing — SC 13G · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Imunon, Inc. Files Q3 2024 10-Q — 10-Q · Nov 7, 2024 Risk: medium
  Imunon, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Celsion Corp, is in the pharmaceutical preparations industr
• Imunon, Inc. Files 8-K: Officer/Director Changes & Compensation — 8-K · Oct 7, 2024 Risk: medium
  Imunon, Inc. filed an 8-K on October 7, 2024, reporting events as of October 2, 2024. The filing covers the departure of directors or certain officers, the elec
• Imunon, Inc. Files S-1/A Amendment — S-1/A · Sep 20, 2024 Risk: medium
  Imunon, Inc. filed an S-1/A amendment on September 20, 2024, for its registration statement. The company, formerly known as Celsion Corp, is incorporated in Del
• Imunon, Inc. Files 8-K Report — 8-K · Sep 3, 2024 Risk: low
  On September 3, 2024, Imunon, Inc. filed an 8-K report detailing "Other Events" and "Financial Statements and Exhibits." The filing does not disclose specific n
• Imunon, Inc. Files S-1 for Public Offering — S-1 · Aug 29, 2024 Risk: medium
  Imunon, Inc. filed an S-1 registration statement on August 29, 2024, to register securities for public offering. The company, formerly known as Celsion Corp, is
• Imunon, Inc. Files Q2 2024 10-Q Report — 10-Q · Aug 14, 2024 Risk: medium
  Imunon, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as Celsion Corp, is in the pharmaceutical preparations industry. Fi
• SC 13G Filing — SC 13G · Aug 5, 2024
• Imunon, Inc. Files 8-K: Procedural Update — 8-K · Aug 1, 2024 Risk: low
  Imunon, Inc. filed an 8-K on August 1, 2024, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific details abou
• Imunon Secures $1.5M in Preferred Stock Financing — 8-K · Jul 31, 2024 Risk: medium
  On July 30, 2024, Imunon, Inc. entered into a Material Definitive Agreement, specifically a Securities Purchase Agreement, with an accredited investor. The agre
• Imunon, Inc. Files 8-K with Regulatory Updates — 8-K · Jul 30, 2024 Risk: low
  Imunon, Inc. filed an 8-K on July 30, 2024, reporting on various events. The filing includes information related to Regulation FD disclosures, other events, and
• Imunon, Inc. Announces Special Stockholder Meeting for Reverse Stock Split — 8-K · Jun 13, 2024 Risk: medium
  On June 13, 2024, Imunon, Inc. filed an 8-K report detailing a special meeting of stockholders scheduled for July 15, 2024. The primary purpose of this meeting
• Imunon, Inc. Announces Director Departure and Election — 8-K · May 20, 2024 Risk: medium
  On May 15, 2024, Imunon, Inc. filed an 8-K report detailing the departure of Director Dr. Nicholas B. Costales and the election of Dr. Jonathan S. Roth as a new
• Imunon, Inc. Files 8-K for Operations and Financials — 8-K · May 13, 2024 Risk: low
  Imunon, Inc. filed an 8-K on May 13, 2024, to report on its results of operations and financial condition, as well as to file financial statements and exhibits.
• Imunon, Inc. Reports Director/Officer Changes & Compensatory Arrangements — 8-K · May 8, 2024 Risk: medium
  Imunon, Inc. filed an 8-K on May 8, 2024, reporting changes effective May 3, 2024. The filing covers the departure of directors or certain officers, the electio
• Imunon, Inc. Announces Virtual Annual Meeting of Stockholders on June 12, 2024 — DEF 14A · Apr 26, 2024 Risk: low
  Imunon, Inc. (IMNN) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. Imunon, Inc. will hold its Annual Meeting of Stockholders virtually on Jun
• Imunon, Inc. Terminates Merger with Eterna Therapeutics — 8-K · Apr 11, 2024 Risk: medium
  On April 10, 2024, Imunon, Inc. announced the termination of its previously announced merger agreement with Eterna Therapeutics, Inc. The termination was effect
• Imunon, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 28, 2024 Risk: medium
  Imunon, Inc. (IMNN) filed a Annual Report (10-K) with the SEC on March 28, 2024. Imunon, Inc. filed its 10-K for the fiscal year ending December 31, 2023. The c
• Imunon, Inc. Files 8-K for Amendments and Financials — 8-K · Mar 18, 2024 Risk: low
  On March 15, 2024, Imunon, Inc. filed an 8-K report detailing amendments to its Articles of Incorporation and financial statements. The company, formerly known
• Imunon, Inc. Reports Board and Executive Changes — 8-K · Mar 12, 2024 Risk: medium
  Imunon, Inc. announced on March 6, 2024, a change in its board of directors and executive compensation arrangements. The filing details the departure of certain
• Imunon, Inc. Files Amendment No. 2 to Form S-1 Registration Statement — S-1/A · Feb 9, 2024 Risk: low
  Imunon, Inc. (IMNN) filed a Amended IPO Registration (S-1/A) with the SEC on February 9, 2024. Imunon, Inc. filed an amendment (No. 2) to its Form S-1 Registrat
• Imunon, Inc. Files Amendment No. 1 to S-1 Registration Statement — S-1/A · Jan 18, 2024 Risk: low
  Imunon, Inc. (IMNN) filed a Amended IPO Registration (S-1/A) with the SEC on January 18, 2024. Imunon, Inc. (formerly Celsion Corp) filed an S-1/A amendment on

Risk Profile

Risk Assessment: Of IMNN's 43 recent filings, 8 were flagged as high-risk, 21 as medium-risk, and 14 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Imunon, INC.'s most recent 10-K filing (Mar 31, 2026):

• Revenue: Not Disclosed
• Net Income: Not Disclosed
• EPS: Not Disclosed
• Debt-to-Equity: Not Disclosed
• Cash Position: Not Disclosed
• Operating Margin: Not Disclosed
• Total Assets: Not Disclosed
• Total Debt: Not Disclosed

Key Executives

• Stacy Lindborg
• Dr. Nicholas B. Costales
• Dr. Jonathan S. Roth
• Corinne Le Goff
• Megan Gates
• Michael Riella
• Ron Ben-Bassat
• Eric Victorson
• Megan Gates, Esq.

Industry Context

Imunon operates in the highly competitive clinical-stage biotechnology sector, focusing on oncology and infectious disease. The company's non-viral DNA and mRNA delivery platform positions it within the rapidly evolving field of advanced therapeutics. Key industry trends include the increasing focus on personalized medicine, immunotherapy, and novel drug delivery systems, driven by significant unmet medical needs in areas like advanced ovarian cancer.

Top Tags

8-k (5) · delisting (5) · financials (5) · filing (5) · sec-filing (5) · regulatory (4) · SEC Filing (4) · 8-K (4) · corporate-governance (4) · Imunon (4)

Key Numbers

• Aggregate market value of common stock held by non-affiliates: $21.2 million — As of June 30, 2025, indicating small market capitalization
• Closing sale price per share of common stock: $10.43 — As of June 30, 2025
• Shares of common stock issued and outstanding: 3,922,764 — As of March 30, 2026
• Disease control rate in OVATION 1 Study: 100% — Observed in 14 patients treated with IMNN-001 plus standard chemotherapy
• Objective response rate (ORR) in OVATION 1 Study: 86% — Observed in 14 patients treated with IMNN-001 plus standard chemotherapy
• Complete tumor resection (R0) rate in OVATION 1 Study: 64% — Observed in 14 patients treated with IMNN-001 plus standard chemotherapy
• ORR in highest dose cohort of OVATION 1 Study: 100% — Observed in five patients treated at the highest dose
• R0 surgical resection rate in highest dose cohort of OVATION 1 Study: 100% — Observed in five patients treated at the highest dose
• New cases of ovarian cancer in the U.S.: 20,000 — Estimated in 2021
• Estimated deaths from ovarian cancer in the U.S.: 13,000 — Estimated in 2021
• Net loss for nine months ended Sep 30, 2025: $10.27M — Decreased from $14.56M in 2024, a 29.5% reduction.
• Research and development expenses for nine months ended Sep 30, 2025: $5.29M — Decreased from $9.41M in 2024, a 43.8% reduction.
• General and administrative expenses for nine months ended Sep 30, 2025: $5.10M — Decreased from $5.58M in 2024, an 8.6% reduction.
• Cash and cash equivalents as of Sep 30, 2025: $5.25M — Down from $5.87M at Dec 31, 2024, indicating declining liquidity.
• Net cash used in operating activities for nine months ended Sep 30, 2025: $10.24M — Reduced from $14.43M in 2024, but still a significant burn.

Forward-Looking Statements

• {"claim":"Imunon, Inc. will initiate a public offering of securities.","entity":"Imunon, Inc.","targetDate":"As soon as practicable after the effective date of this registration statement.","confidence":"high"}
• {"claim":"The offering will be conducted on a delayed or continuous basis.","entity":"Imunon, Inc.","targetDate":"Ongoing","confidence":"high"}

Related Companies

IMUN · IMNL

Frequently Asked Questions